Niklas Victoria Ninon Olivia 4

What Happened

• Niklas Victoria Ninon Olivia, a director of FibroBiologics, was granted 30,803 derivative securities (reported as an Award/Grant, code A) on 2026-06-23. The award shows an acquisition price of $0.00 (no cash paid).
• This is a compensation grant from the company (not an open-market buy or sale). Such grants are typically used for pay/retention rather than an immediate bullish or bearish trading signal.

Key Details

• Transaction date: 2026-06-23; reported filing date: 2026-06-23 (timely).
• Amount: 30,803 derivative shares; Price: $0.00 (no cash exchanged).
• Vesting: Per footnote, the award vests in full upon the earlier of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Transaction type: A = Award/Grant (derivative security). No 10b5-1 plan, tax-withholding, or late-filing flags noted in the provided data.

Context

• Derivative awards may be options, restricted stock units, or similar instruments that convert to or allow purchase of common shares after vesting/exercise; this filing reports the grant itself, not an exercise or sale.
• Awards are common executive/director compensation and do not by themselves indicate immediate buying or selling intent. The vesting schedule is meant to align incentives/retention across the coming year.